Linda Chang1, Caroline Jiang2, Eric Cunningham2, Steven Buchthal2, Vanessa Douet2, Marilou Andres2, Thomas Ernst2. 1. From the Department of Medicine, Division of Neurology, John A. Burns School of Medicine (L.C., C.J., E.C., S.B., V.D., T.E.), and Pacific Biosciences Research Center (M.A.), University of Hawai'i at Manoa, and The Queen's Medical Center, Honolulu, HI. lchang@hawaii.edu. 2. From the Department of Medicine, Division of Neurology, John A. Burns School of Medicine (L.C., C.J., E.C., S.B., V.D., T.E.), and Pacific Biosciences Research Center (M.A.), University of Hawai'i at Manoa, and The Queen's Medical Center, Honolulu, HI.
Abstract
OBJECTIVE: We aimed to evaluate the combined effects of HIV and APOE ε4 allele(s) on glial metabolite levels, and on known cognitive deficits associated with either condition, across the ages. METHODS: One hundred seventy-seven participants, primarily of white and mixed race (97 seronegative subjects: aged 44.7 ± 1.3 years, 85 [87.6%] men, 28 [28.9%] APOE ε4+; 80 HIV+ subjects: aged 47.3 ± 1.1 years, 73 [91.3%] men, 23 [28.8%] APOE ε4+), were assessed cross-sectionally for metabolite concentrations using proton magnetic resonance spectroscopy in 4 brain regions and for neuropsychological performance. RESULTS: Frontal white matter myo-inositol was elevated in subjects with HIV across the age span but showed age-dependent increase in seronegative subjects, especially in APOE ε4+ carriers. In contrast, only seronegative APOE ε4+ subjects showed elevated myo-inositol in parietal cortex. All APOE ε4+ subjects had lower total creatine in basal ganglia. While all HIV subjects showed greater cognitive deficits, HIV+ APOE ε4+ subjects had the poorest executive function, fluency memory, and attention/working memory. Higher myo-inositol levels were associated with poorer fine motor function across all subjects, slower speed of information processing in APOE ε4+ subjects, and worse fluency in HIV+ APOE ε4+ subjects. CONCLUSIONS: In frontal white matter of subjects with HIV, the persistent elevation and lack of normal age-dependent increase in myo-inositol suggest that persistent glial activation attenuated the typical antagonistic pleiotropic effects of APOE ε4 on neuroinflammation. APOE ε4 negatively affects energy metabolism in brain regions rich in dopaminergic synapses. The combined effects of HIV infection and APOE ε4 may lead to greater cognitive deficits, especially in those with greater neuroinflammation. APOE ε4 allele(s) may be a useful genetic marker to identify white and mixed-race HIV subjects at risk for cognitive decline.
OBJECTIVE: We aimed to evaluate the combined effects of HIV and APOE ε4 allele(s) on glial metabolite levels, and on known cognitive deficits associated with either condition, across the ages. METHODS: One hundred seventy-seven participants, primarily of white and mixed race (97 seronegative subjects: aged 44.7 ± 1.3 years, 85 [87.6%] men, 28 [28.9%] APOE ε4+; 80 HIV+ subjects: aged 47.3 ± 1.1 years, 73 [91.3%] men, 23 [28.8%] APOE ε4+), were assessed cross-sectionally for metabolite concentrations using proton magnetic resonance spectroscopy in 4 brain regions and for neuropsychological performance. RESULTS: Frontal white matter myo-inositol was elevated in subjects with HIV across the age span but showed age-dependent increase in seronegative subjects, especially in APOE ε4+ carriers. In contrast, only seronegative APOE ε4+ subjects showed elevated myo-inositol in parietal cortex. All APOE ε4+ subjects had lower total creatine in basal ganglia. While all HIV subjects showed greater cognitive deficits, HIV+ APOE ε4+ subjects had the poorest executive function, fluency memory, and attention/working memory. Higher myo-inositol levels were associated with poorer fine motor function across all subjects, slower speed of information processing in APOE ε4+ subjects, and worse fluency in HIV+ APOE ε4+ subjects. CONCLUSIONS: In frontal white matter of subjects with HIV, the persistent elevation and lack of normal age-dependent increase in myo-inositol suggest that persistent glial activation attenuated the typical antagonistic pleiotropic effects of APOE ε4 on neuroinflammation. APOE ε4 negatively affects energy metabolism in brain regions rich in dopaminergic synapses. The combined effects of HIV infection and APOE ε4 may lead to greater cognitive deficits, especially in those with greater neuroinflammation. APOE ε4 allele(s) may be a useful genetic marker to identify white and mixed-race HIV subjects at risk for cognitive decline.
Authors: Virawudh Soontornniyomkij; David J Moore; Ben Gouaux; Benchawanna Soontornniyomkij; Erick T Tatro; Anya Umlauf; Eliezer Masliah; Andrew J Levine; Elyse J Singer; Harry V Vinters; Benjamin B Gelman; Susan Morgello; Mariana Cherner; Igor Grant; Cristian L Achim Journal: AIDS Date: 2012-11-28 Impact factor: 4.177
Authors: E-M Ratai; S Pilkenton; J He; R Fell; J P Bombardier; C-G Joo; M R Lentz; W-K Kim; T H Burdo; P Autissier; L Annamalai; E Curran; S P O'Neil; S V Westmoreland; K C Williams; E Masliah; R Gilberto González Journal: J Med Primatol Date: 2011-04-04 Impact factor: 0.667
Authors: Neda Jahanshad; Victor G Valcour; Talia M Nir; Omid Kohannim; Edgar Busovaca; Krista Nicolas; Paul M Thompson Journal: Brain Connect Date: 2012
Authors: P Cinque; L Vago; M Mengozzi; V Torri; D Ceresa; E Vicenzi; P Transidico; A Vagani; S Sozzani; A Mantovani; A Lazzarin; G Poli Journal: AIDS Date: 1998-07-30 Impact factor: 4.177
Authors: E E Morgan; S P Woods; S L Letendre; D R Franklin; C Bloss; A Goate; R K Heaton; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; R J Ellis; I Abramson; A Gamst; C Fennema-Notestine; D M Smith; I Grant; F Vaida; D B Clifford Journal: J Neurovirol Date: 2013-02-14 Impact factor: 2.643
Authors: M P Laakso; Y Hiltunen; M Könönen; M Kivipelto; A Koivisto; M Hallikainen; H Soininen Journal: J Neural Transm (Vienna) Date: 2003-03 Impact factor: 3.575
Authors: Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong Journal: Neuropsychopharmacology Date: 2015-02-27 Impact factor: 7.853
Authors: Uraina S Clark; Keenan A Walker; Ronald A Cohen; Kathryn N Devlin; Anna M Folkers; Matthew J Pina; Karen T Tashima Journal: Neuropsychologia Date: 2015-03-03 Impact factor: 3.139
Authors: Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2015-08-28 Impact factor: 9.306